The Austin, Texas-based medical device company posted profits of $9.1 million, or 27¢ per share, on sales of $86.9 million during the 3 months ended Sept. 30. That represents a 4.4% increase in sales and 477.9% bottom-line growth.
The major impact on the bottom line came from a $6.3 million reduction in operating expenses related to lower "investigation and restatement-related costs," the company said.
A pair of former ArthroCare executives, John Raffle and David Applegate, are accused of inflating the company’s earnings by 10s of millions of dollars through sham transactions with distributors from around December 2005 to December 2008. The scandal forced ArthroCare to restate its financials for those years, and has been a drag on profits ever since the scandal broke in 2008.
The news sent ARTC shares up 6.4% today to a $31.99 close on Wall Street.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.